(1E,6E)-1-[3-hydroxy-4-(hydroxymethyl)phenyl]-7-(3-hydroxy-4-methoxyphenyl)hepta-1,6-diene-3,5-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: (1E,6E)-1-[3-hydroxy-4-(hydroxymethyl)phenyl]-7-(3-hydroxy-4-methoxyphenyl)hepta-1,6-diene-3,5-dione
• 化学式: C₂₁H₂₀O₆
• 分子量: 368.4
• InChiKey: BQXRVEXQRAKAEE-FCXRPNKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• COMPOSITIONS AND METHODS FOR TREATING CANCER
  申请人：Santen Richard J.

  公开号：US20140161827A1

  公开（公告）日：2014-06-12

  The present invention provides combination therapies useful for treating cancer, particularly breast cancer. The invention provides, in various embodiments, methods of treating a cancer, comprising administering to a patient afflicted therewith of an effective amount an immunoconjugate comprising a monoclonal antibody moiety and a first pro-apoptotic drug moiety linked thereto; and administering to the patient an effective amount of a second pro-apoptotic drug. The monoclonal antibody moiety of the immunoconjugate can act to target receptors of hormone-resistant breast cancer cells, such as HER2. Synergistic effects can be seen when the two pro-apoptotic drugs, acting by a common molecular mechanism (vertical modulation) or different molecular mechanisms (horizontal modulation) are administered to patients afflicted by breast cancer, such as hormone-resistant breast cancer.